Upstream Bio, Inc./$UPB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Ticker
$UPB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
52
ISIN
US91678A1079
Website
UPB Metrics
BasicAdvanced
$572M
-
-$3.40
-
-
Price and volume
Market cap
$572M
52-week high
$12.10
52-week low
$5.14
Average daily volume
363K
Financial strength
Current ratio
47.433
Quick ratio
45.272
Long term debt to equity
0.223
Total debt to equity
0.381
Profitability
EBITDA (TTM)
-94.645
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,448.69%
Operating margin (TTM)
-4,127.35%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on equity (TTM)
-28.62%
Valuation
Price to revenue (TTM)
122.055
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-3.365
Free cash flow yield (TTM)
-29.72%
Free cash flow per share (TTM)
-316.22%
Growth
Revenue change (TTM)
-2.94%
Earnings per share change (TTM)
-76.64%
Bulls say / Bears say
Upstream Bio's lead candidate, verekitug, is progressing through Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, with top-line data expected in the second half of 2025 and 2026, respectively, potentially positioning the company as a leader in these therapeutic areas. (reuters.com)
The company successfully completed an upsized IPO in October 2024, raising approximately $293 million, providing a strong financial foundation to support ongoing and future clinical programs. (globenewswire.com)
Analysts have initiated coverage with positive ratings; for instance, JPMorgan Chase & Co. set an 'overweight' rating and a $38.00 price target, indicating confidence in the company's growth prospects. (americanbankingnews.com)
In Q1 2025, Upstream Bio reported a net loss of $27.27 million, a 150.3% increase from the previous year's loss, raising concerns about the company's financial sustainability. (ainvest.com)
The company's revenue in 2024 was $2.37 million, a slight decrease from the previous year, indicating challenges in generating significant income from its operations. (marketscreener.com)
Despite a strong IPO debut, the stock price has experienced volatility, with a notable decline from its initial trading price, reflecting potential investor concerns about the company's long-term prospects. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
UPB News
AllArticlesVideos
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
GlobeNewsWire·6 days ago
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
GlobeNewsWire·2 weeks ago
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Upstream Bio, Inc. stock?
Upstream Bio, Inc. (UPB) has a market cap of $572M as of June 21, 2025.
What is the P/E ratio for Upstream Bio, Inc. stock?
The price to earnings (P/E) ratio for Upstream Bio, Inc. (UPB) stock is 0 as of June 21, 2025.
Does Upstream Bio, Inc. stock pay dividends?
No, Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Upstream Bio, Inc. dividend payment date?
Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders.
What is the beta indicator for Upstream Bio, Inc.?
Upstream Bio, Inc. (UPB) does not currently have a Beta indicator.